Quark will present at TIDES: Oligonucleotide Therapeutics Discovery. Providence, RI, May 12-15, 2014.
Use of siRNA for Treatment of Inner Ear Diseases.
Quark Pharmaceuticals to Participate in IBC’s Oligonucleotide Therapeutics: From Concept to Implementation Conference
Fremont, CA – August 3, 2009 – Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced that James D. Thompson, Ph.D., Vice President, Pharmaceutical Development, will participate in multiple roles at IBC’s Oligonucleotide Therapeutics: from Concept to Implementation Conference. The conference will take place August 3-5, 2009 in […]
Quark Pharmaceuticals Presented At ARVO Data Showing That PF-04523655 Enters Retinal Cells And Elicits Its Pharmacologic Effect Via Target Gene Knock-Down Without Activating TLR3
Fremont, CA – May 11, 2009 – Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced that Elena Feinstein, M.D., Ph.D., Chief Scientific Officer, presented a study titled, “PF-04523655 (REDD14NP), an siRNA Compound Targeting RTP801, Penetrates Retinal Cells Producing Target Gene Knockdown and Avoiding TLR3 Activation,” at […]
Quark Pharmaceuticals Presents at American Society for Pharmacology and Experimental Therapeutics Annual Meeting
Fremont, CA – April 20, 2009 – Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced that James D. Thompson, Ph.D., Vice President, Pharmaceutical Development, will give a presentation on Tuesday, April 21 at this year’s American Society for Pharmacology and Experimental Therapeutics (ASPET) Annual Meeting, which […]
Quark Pharmaceuticals Presents at Asia TIDES Conference
Highlights First Systemic siRNA Administered in Humans and Quark’s Proprietary siRNA Structures
Fremont, CA – March 9, 2009 – Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced that James D. Thompson, Ph.D., Vice President, Pharmaceutical Development presented an overview of Quark’s novel pipeline of synthetic siRNA compounds […]
Quark Pharmaceuticals to Present at the 20th Annual Piper Jaffray Health Care Conference
Presentation to Highlight Results of Ocular Neuroprotection Candidate
Fremont, CA (December 1, 2008) – Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced that its Chief Operating Officer, Dr. Rami Skaliter is scheduled to present results on the Company’s ocular neuroprotection candidate at the 20th Annual Piper Jaffray […]
Quark Pharmaceuticals Announces Poster Presentations at RNAi Europe 2008
Quark Pharmaceuticals Announces Poster Presentations at RNAI Europe 2008
Fremont, California, September 17, 2008 – Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced the presentation of posters at the 5th Annual RNAi Europe, taking place September 16-18, 2008 in Stockholm, Sweden. Three of Quark’s scientists, Igor Mett, […]
Quark to Present at JPMorgan 26th Annual Healthcare Conference
Preclinical Developments to be Highlighted: Delivery of siRNA to Bone Marrow and Proof of Concept Study Results –
Fremont, California, December 20, 2007 – Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company engaged in discovering and developing novel therapeutic RNAi drug candidates, announced today that it is scheduled to present at the JPMorgan 26th Annual Healthcare Conference on […]
Quark to Present at CIBC and Acumen BioFin Rodman & Renshaw
Fremont, California, October 9, 2007 – Quark Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing novel RNA interference-based therapeutics, announced today that it is scheduled to present on Tuesday, November 6, 2007 at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference and the CIBC World Markets 18th Annual Healthcare Conference. […]